{"transactions":[{"id":4627794,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-28T21:15:06.000Z","date":"2026-09-24","kind":"grant","planned":false,"acquired":true,"shares":145500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":145500,"derivative":{"exercise_price":3.39,"expiration_date":"2036-09-23","underlying":"Common Stock","underlying_shares":145500},"source":{"system":"sec-edgar","filing":"0001995218-26-000017","document":"form4-09282026_050901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1995218/000199521826000017/form4-09282026_050901.xml","form_type":"4"}},{"id":4627793,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-28T21:15:06.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":2306,"price":2.644,"value":6097.064,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 242,911 Restricted Stock Units."}],"balance_after":376778,"source":{"system":"sec-edgar","filing":"0001995218-26-000017","document":"form4-09282026_050901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1995218/000199521826000017/form4-09282026_050901.xml","form_type":"4"}},{"id":680749,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-19T21:00:11.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":3345,"price":4.9512,"value":16561.764,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.83 to $5.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 242,911 Restricted Stock Units."}],"balance_after":374472,"source":{"system":"sec-edgar","filing":"0001995218-26-000015","document":"form4-08192026_050805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000015/form4-08192026_050805.xml","form_type":"4"}},{"id":720536,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-01T22:47:19.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":25947,"price":4.48,"value":116242.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of performance Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.3402 to $4.7507. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 252,130 RSUs.  Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":377817,"source":{"system":"sec-edgar","filing":"0001995218-26-000013","document":"form4-07012026_100715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000013/form4-07012026_100715.xml","form_type":"4"}},{"id":720535,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-01T22:47:19.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":403764,"source":{"system":"sec-edgar","filing":"0001995218-26-000013","document":"form4-07012026_100715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000013/form4-07012026_100715.xml","form_type":"4"}},{"id":769324,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:30:12.000Z","date":"2026-05-18","kind":"sale","planned":false,"acquired":false,"shares":3342,"price":5.0649,"value":16926.8958,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $5.03 to $5.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 252,130 Restricted Stock Units."}],"balance_after":336764,"source":{"system":"sec-edgar","filing":"0001995218-26-000011","document":"form4-05202026_040505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000011/form4-05202026_040505.xml","form_type":"4"}},{"id":813071,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-07T20:55:07.000Z","date":"2026-04-06","kind":"sale","planned":true,"acquired":false,"shares":55000,"price":5.6934,"value":313137.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $5.56 to $5.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 261,349 Restricted Stock Units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":340106,"source":{"system":"sec-edgar","filing":"0001995218-26-000009","document":"form4-04072026_040401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000009/form4-04072026_040401.xml","form_type":"4"}},{"id":836449,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-18T01:22:39.000Z","date":"2026-03-13","kind":"grant","planned":false,"acquired":true,"shares":2623,"price":2.644,"value":6935.212,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 261,349 Restricted Stock Units."}],"balance_after":395106,"source":{"system":"sec-edgar","filing":"0001995218-26-000006","document":"form4-03182026_010332.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000006/form4-03182026_010332.xml","form_type":"4"}},{"id":890056,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-20T22:05:07.000Z","date":"2026-02-18","kind":"sale","planned":false,"acquired":false,"shares":10173,"price":6.382,"value":64924.086,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $6.22 to $6.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 261,349 Restricted Stock Units."}],"balance_after":392483,"source":{"system":"sec-edgar","filing":"0001995218-26-000004","document":"form4-02202026_050203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000004/form4-02202026_050203.xml","form_type":"4"}},{"id":915628,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-06T22:00:12.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":646665,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":646665,"derivative":{"exercise_price":7.27,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001995218-26-000002","document":"form4-02062026_050205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000002/form4-02062026_050205.xml","form_type":"4"}},{"id":915627,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-06T22:00:12.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":161665,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 290,022 RSUs."}],"balance_after":402656,"source":{"system":"sec-edgar","filing":"0001995218-26-000002","document":"form4-02062026_050205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521826000002/form4-02062026_050205.xml","form_type":"4"}},{"id":992158,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-20T22:21:29.000Z","date":"2025-11-18","kind":"sale","planned":false,"acquired":false,"shares":1127,"price":9.27,"value":10447.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 128,357 Restricted Stock Units."}],"balance_after":240991,"source":{"system":"sec-edgar","filing":"0001995218-25-000007","document":"form4-11202025_101125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521825000007/form4-11202025_101125.xml","form_type":"4"}},{"id":1016221,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-17T23:26:05.000Z","date":"2025-10-17","kind":"sale","planned":false,"acquired":false,"shares":148,"price":9.561,"value":1415.028,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 131,092 RSUs.  Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":242118,"source":{"system":"sec-edgar","filing":"0001995218-25-000005","document":"form4-10172025_111000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521825000005/form4-10172025_111000.xml","form_type":"4"}},{"id":1016220,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-17T23:26:05.000Z","date":"2025-10-17","kind":"sale","planned":false,"acquired":false,"shares":12985,"price":8.935,"value":116020.975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":242266,"source":{"system":"sec-edgar","filing":"0001995218-25-000005","document":"form4-10172025_111000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521825000005/form4-10172025_111000.xml","form_type":"4"}},{"id":1016219,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-17T23:26:05.000Z","date":"2025-10-15","kind":"grant","planned":false,"acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":255251,"source":{"system":"sec-edgar","filing":"0001995218-25-000005","document":"form4-10172025_111000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521825000005/form4-10172025_111000.xml","form_type":"4"}},{"id":1038934,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-16T21:30:06.000Z","date":"2025-09-12","kind":"grant","planned":false,"acquired":true,"shares":2193,"price":2.644,"value":5798.292,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 131,092 Restricted Stock Units."}],"balance_after":222251,"source":{"system":"sec-edgar","filing":"0001995218-25-000003","document":"form4-09162025_050903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000199521825000003/form4-09162025_050903.xml","form_type":"4"}},{"id":1043649,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-10T20:59:33.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":1115,"price":4.668,"value":5204.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"On August 20, 2025, the reporting person filed a Form 4 which inadvertently reported the disposition of 2,735 securities. In fact, as reported in this amendment, the reporting person disposed of 1,115 shares of Common Stock on August 18, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 131,092 Restricted Stock Units."}],"balance_after":220058,"source":{"system":"sec-edgar","filing":"0001415889-25-024104","document":"form4a-09102025_080929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925024104/form4a-09102025_080929.xml","form_type":"4/A","original_submission_date":"2025-08-20"}},{"id":1059800,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-08-20T21:00:18.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":2735,"price":4.668,"value":12766.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 131,092 RSUs."}],"balance_after":220058,"source":{"system":"sec-edgar","filing":"0001415889-25-022473","document":"form4-08202025_090813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925022473/form4-08202025_090813.xml","form_type":"4"}},{"id":1139911,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-05-20T21:00:15.000Z","date":"2025-05-16","kind":"sale","planned":false,"acquired":false,"shares":1074,"price":2.774,"value":2979.276,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 133,827 RSUs."}],"balance_after":221173,"source":{"system":"sec-edgar","filing":"0001415889-25-013819","document":"form4-05202025_050509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925013819/form4-05202025_050509.xml","form_type":"4"}},{"id":1185839,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-01T23:58:17.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":2128,"price":2.61,"value":5554.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."}],"balance_after":222247,"source":{"system":"sec-edgar","filing":"0001415889-25-009450","document":"form4-04012025_110414.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925009450/form4-04012025_110414.xml","form_type":"4"}},{"id":1252063,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-21T22:10:25.000Z","date":"2025-02-19","kind":"sale","planned":false,"acquired":false,"shares":4326,"price":4.413,"value":19090.638,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale to cover tax obligations on the release of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 136,562 RSUs."}],"balance_after":220119,"source":{"system":"sec-edgar","filing":"0001415889-25-005113","document":"form4-02212025_100221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925005113/form4-02212025_100221.xml","form_type":"4"}},{"id":1304801,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-10T21:55:14.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":207500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest and become exercisable on January 7, 2026, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":207500,"derivative":{"exercise_price":7.33,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":207500},"source":{"system":"sec-edgar","filing":"0001415889-25-001287","document":"form4-01102025_040110.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925001287/form4-01102025_040110.xml","form_type":"4"}},{"id":1304800,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-10T21:55:14.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":103750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 147,500 RSUs."}],"balance_after":224445,"source":{"system":"sec-edgar","filing":"0001415889-25-001287","document":"form4-01102025_040110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588925001287/form4-01102025_040110.xml","form_type":"4"}},{"id":1333362,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-12-12T22:00:09.000Z","date":"2024-12-10","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":118655,"derivative":{"exercise_price":2.33,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001415889-24-029143","document":"form4-12122024_051206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924029143/form4-12122024_051206.xml","form_type":"4"}},{"id":1333361,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-12T22:00:09.000Z","date":"2024-12-10","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":8.1965,"value":20491.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $7.98 to $8.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":120695,"source":{"system":"sec-edgar","filing":"0001415889-24-029143","document":"form4-12122024_051206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924029143/form4-12122024_051206.xml","form_type":"4"}},{"id":1333360,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-12T22:00:09.000Z","date":"2024-12-10","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":2.33,"value":5825.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."}],"balance_after":123195,"source":{"system":"sec-edgar","filing":"0001415889-24-029143","document":"form4-12122024_051206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924029143/form4-12122024_051206.xml","form_type":"4"}},{"id":1366099,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-13T22:33:29.000Z","date":"2024-11-11","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":121155,"derivative":{"exercise_price":2.33,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001415889-24-026737","document":"form4-11132024_101126.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924026737/form4-11132024_101126.xml","form_type":"4"}},{"id":1366098,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-11-13T22:33:29.000Z","date":"2024-11-11","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":7.8227,"value":19556.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $7.49 to $8.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":120695,"source":{"system":"sec-edgar","filing":"0001415889-24-026737","document":"form4-11132024_101126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924026737/form4-11132024_101126.xml","form_type":"4"}},{"id":1366097,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-11-13T22:33:29.000Z","date":"2024-11-11","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":2.33,"value":5825.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."}],"balance_after":123195,"source":{"system":"sec-edgar","filing":"0001415889-24-026737","document":"form4-11132024_101126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924026737/form4-11132024_101126.xml","form_type":"4"}},{"id":1386417,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-10-15T17:45:05.000Z","date":"2024-10-10","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":123655,"derivative":{"exercise_price":2.33,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-24-025110","document":"form4-10152024_011001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924025110/form4-10152024_011001.xml","form_type":"4"}},{"id":1386416,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-10-15T17:45:05.000Z","date":"2024-10-10","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":8.0991,"value":40495.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $7.99 to $8.3591. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":120695,"source":{"system":"sec-edgar","filing":"0001415889-24-025110","document":"form4-10152024_011001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924025110/form4-10152024_011001.xml","form_type":"4"}},{"id":1386415,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-10-15T17:45:05.000Z","date":"2024-10-10","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":2.33,"value":11650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."}],"balance_after":125695,"source":{"system":"sec-edgar","filing":"0001415889-24-025110","document":"form4-10152024_011001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924025110/form4-10152024_011001.xml","form_type":"4"}},{"id":1409319,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-11T21:17:04.000Z","date":"2024-09-10","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":128655,"derivative":{"exercise_price":2.33,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-24-023233","document":"form4-09112024_090900.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924023233/form4-09112024_090900.xml","form_type":"4"}},{"id":1409318,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-11T21:17:04.000Z","date":"2024-09-10","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":10.6547,"value":53273.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $10.37 to $10.925. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":120695,"source":{"system":"sec-edgar","filing":"0001415889-24-023233","document":"form4-09112024_090900.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924023233/form4-09112024_090900.xml","form_type":"4"}},{"id":1409317,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-11T21:17:04.000Z","date":"2024-09-10","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":2.33,"value":11650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."}],"balance_after":125695,"source":{"system":"sec-edgar","filing":"0001415889-24-023233","document":"form4-09112024_090900.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924023233/form4-09112024_090900.xml","form_type":"4"}},{"id":1434425,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-13T22:34:04.000Z","date":"2024-08-12","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":133655,"derivative":{"exercise_price":2.33,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-24-021245","document":"form4-08132024_100801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924021245/form4-08132024_100801.xml","form_type":"4"}},{"id":1434424,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-13T22:34:04.000Z","date":"2024-08-12","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":11.5269,"value":57634.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $11.05 to $11.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":120695,"source":{"system":"sec-edgar","filing":"0001415889-24-021245","document":"form4-08132024_100801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924021245/form4-08132024_100801.xml","form_type":"4"}},{"id":1434423,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-13T22:34:04.000Z","date":"2024-08-12","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":2.33,"value":11650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."}],"balance_after":125695,"source":{"system":"sec-edgar","filing":"0001415889-24-021245","document":"form4-08132024_100801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924021245/form4-08132024_100801.xml","form_type":"4"}},{"id":1455107,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-07-12T20:55:07.000Z","date":"2024-07-10","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":138655,"derivative":{"exercise_price":2.33,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-24-019526","document":"form4-07122024_040703.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924019526/form4-07122024_040703.xml","form_type":"4"}},{"id":1455106,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-12T20:55:07.000Z","date":"2024-07-11","kind":"sale","planned":true,"acquired":false,"shares":100,"price":19.06,"value":1906.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":120695,"source":{"system":"sec-edgar","filing":"0001415889-24-019526","document":"form4-07122024_040703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924019526/form4-07122024_040703.xml","form_type":"4"}},{"id":1455105,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-12T20:55:07.000Z","date":"2024-07-11","kind":"sale","planned":true,"acquired":false,"shares":27931,"price":17.06,"value":476502.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $16.7476 to $17.4703. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":120795,"source":{"system":"sec-edgar","filing":"0001415889-24-019526","document":"form4-07122024_040703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924019526/form4-07122024_040703.xml","form_type":"4"}},{"id":1455104,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-12T20:55:07.000Z","date":"2024-07-10","kind":"sale","planned":true,"acquired":false,"shares":3347,"price":16.85,"value":56396.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $16.83 to $16.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":148726,"source":{"system":"sec-edgar","filing":"0001415889-24-019526","document":"form4-07122024_040703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924019526/form4-07122024_040703.xml","form_type":"4"}},{"id":1455103,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-12T20:55:07.000Z","date":"2024-07-10","kind":"sale","planned":true,"acquired":false,"shares":23622,"price":16.45,"value":388581.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $15.83 to $16.825. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":152073,"source":{"system":"sec-edgar","filing":"0001415889-24-019526","document":"form4-07122024_040703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924019526/form4-07122024_040703.xml","form_type":"4"}},{"id":1455102,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-12T20:55:07.000Z","date":"2024-07-10","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":2.33,"value":11650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."}],"balance_after":175695,"source":{"system":"sec-edgar","filing":"0001415889-24-019526","document":"form4-07122024_040703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924019526/form4-07122024_040703.xml","form_type":"4"}},{"id":1481583,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-12T21:00:06.000Z","date":"2024-06-10","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":143655,"derivative":{"exercise_price":2.33,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-24-016518","document":"form4-06122024_050602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924016518/form4-06122024_050602.xml","form_type":"4"}},{"id":1481582,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-06-12T21:00:06.000Z","date":"2024-06-10","kind":"sale","planned":true,"acquired":false,"shares":2038,"price":18.18,"value":37050.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $17.78 to $18.67. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":170695,"source":{"system":"sec-edgar","filing":"0001415889-24-016518","document":"form4-06122024_050602.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924016518/form4-06122024_050602.xml","form_type":"4"}},{"id":1481581,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-06-12T21:00:06.000Z","date":"2024-06-10","kind":"sale","planned":true,"acquired":false,"shares":2962,"price":17.29,"value":51212.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $16.80 to $17.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":172733,"source":{"system":"sec-edgar","filing":"0001415889-24-016518","document":"form4-06122024_050602.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924016518/form4-06122024_050602.xml","form_type":"4"}},{"id":1481580,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-06-12T21:00:06.000Z","date":"2024-06-10","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":2.33,"value":11650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."}],"balance_after":175695,"source":{"system":"sec-edgar","filing":"0001415889-24-016518","document":"form4-06122024_050602.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000141588924016518/form4-06122024_050602.xml","form_type":"4"}},{"id":1516905,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-14T20:04:56.000Z","date":"2024-05-13","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":2.33,"value":11650.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":148655,"derivative":{"exercise_price":2.33,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000950170-24-059506","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024059506/ownership.xml","form_type":"4"}},{"id":1516904,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-14T20:04:56.000Z","date":"2024-05-13","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":13.2186,"value":66093.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $12.98 to $13.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission,\nthe Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":170695,"source":{"system":"sec-edgar","filing":"0000950170-24-059506","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024059506/ownership.xml","form_type":"4"}},{"id":1516903,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-14T20:04:56.000Z","date":"2024-05-13","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":2.33,"value":11650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023."}],"balance_after":175695,"source":{"system":"sec-edgar","filing":"0000950170-24-059506","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024059506/ownership.xml","form_type":"4"}},{"id":1682158,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-09T23:52:31.000Z","date":"2024-01-05","kind":"grant","planned":true,"acquired":true,"shares":262500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option shall vest on January 5, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":262500,"derivative":{"exercise_price":14.48,"expiration_date":"2034-01-04","underlying":"Common Stock","underlying_shares":262500},"source":{"system":"sec-edgar","filing":"0000950170-24-003466","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024003466/ownership.xml","form_type":"4"}},{"id":1682157,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":21481,"kind":"person","name":"Townsend Richard Nolan","position":1,"cik":"0001995218","reported_name":"Townsend Richard Nolan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-09T23:52:31.000Z","date":"2024-01-05","kind":"grant","planned":true,"acquired":true,"shares":43750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2025, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total represents 126,945 shares of Common Stock and 43,750 RSUs."}],"balance_after":170695,"source":{"system":"sec-edgar","filing":"0000950170-24-003466","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024003466/ownership.xml","form_type":"4"}}]}